蔗糖铁联合使用重组人促红细胞生成素治疗老年髋部骨折贫血的临床疗效观察
摘要点击次数: 1789   全文下载次数: 875   投稿时间:2018-08-20    
作者Author单位AddressE-Mail
徐鸿尧 XU Hong-yao 南京医科大学附属南京医院 南京市第一医院, 江苏 南京 210006 Nanjing Hospital Affiliated to Nanjing Medical University, Nanjing First Hospital, Nanjing 210006, Jiangsu, China  
戴志宏 DAI Zhi-hong 南京医科大学附属南京医院 南京市第一医院, 江苏 南京 210006 Nanjing Hospital Affiliated to Nanjing Medical University, Nanjing First Hospital, Nanjing 210006, Jiangsu, China  
黄河 HUANG He 南京医科大学附属南京医院 南京市第一医院, 江苏 南京 210006 Nanjing Hospital Affiliated to Nanjing Medical University, Nanjing First Hospital, Nanjing 210006, Jiangsu, China 342482410@qq.com 
期刊信息:《中国骨伤》2019年,第32卷,第5期,第444-447页
DOI:10.3969/j.issn.1003-0034.2019.05.011
基金项目:
中文摘要:

目的:分析蔗糖铁联合使用重组人促红细胞生成素治疗老年髋部骨折贫血的临床疗效。

方法:自2016年2月至2018年4月行髋部骨折手术96例老年贫血患者根据治疗方式分为3组,3组患者均在术前3 d接受抗贫血治疗,其中A组32例单独使用蔗糖铁,B组32例单独使用重组人促红细胞生成素,C组32例联合使用蔗糖铁和重组人促红细胞生成素治疗,观察比较3组的治疗效果。

结果:临床有效率C组显著高于A、B组患者(P<0.05)。3组患者围术期失血量比较,差异无统计学意义(P>0.05),但C组输血率明显低于A、B组患者(P<0.05)。用药前,3组血红蛋白、红细胞计数比较,差异无统计学意义(P>0.05),但术后1、3、5 d,C组患者上述指标均明显高于A、B组(P<0.05)。用药期间,药物不良反应发生率3组间差异无统计学意义(P>0.05)。

结论:与单一用药相比,蔗糖铁联合使用重组人促红细胞生成素治疗老年髋部骨折贫血效果确切,不仅能够有效改善患者血红蛋白水平,保障手术顺利进行,还可降低患者的输血率,促进其术后康复。
【关键词】髋骨折  贫血  促红细胞生成素  蔗糖铁
 
Clinical observation of iron sucrose combined with recombinant human erythropoietin in the treatment of anemia of hip fracture in elderly patients
ABSTRACT  

Objective:To explore the clinical efficacy of iron sucrose combined with recombinant human erythropoietin(EPO) for the treatment of anemia in elderly patients with hip fracture.

Methods:From February 2016 to April 2018,96 elderly anemia patients who underwent hip fracture surgery were divided into three groups according to the treatment methods. All the three groups received anti-anemia treatment 3 days before operation. Among them,32 cases in group A were treated with iron sucrose alone,32 cases in group B were treated with recombinant human erythropoietin alone,and 32 cases in group C were treated with iron sucrose combined with recombinant human erythropoietin. The therapeutic effects of the three groups were observed and compared.

Results:The clinical effective rate in group C was significantly higher than that in group A and B (P<0.05). There was no significant difference in perioperative blood loss among the three groups(P>0.05),but the transfusion rate in group C was significantly lower than that in group A and B (P<0.05). There was no significant difference in hemoglobin and erythrocyte counts among the three groups before treatment(P>0.05),but the above indexes in group C were significantly higher than those in group A and B(P<0.05) at 1,3 and 5 days after operation. There was no significant difference in the incidence of adverse drug reactions among the three groups(P>0.05).

Conclusion:Compared with single drug,the combined use of sucrose and iron and recombinant human erythropoietin in the treatment of elderly hip fracture anemia has a definite effect. It can not only effectively improve the level of hemoglobin,ensure the smooth operation,but also reduce the blood transfusion rate of patients and promote their recovery after operation.
KEY WORDS  Hip fractures  Anemia  Erythropoietin  Iron sucrose
 
引用本文,请按以下格式著录参考文献:
中文格式:徐鸿尧,戴志宏,黄河.蔗糖铁联合使用重组人促红细胞生成素治疗老年髋部骨折贫血的临床疗效观察[J].中国骨伤,2019,32(5):444~447
英文格式:XU Hong-yao,DAI Zhi-hong,HUANG He.Clinical observation of iron sucrose combined with recombinant human erythropoietin in the treatment of anemia of hip fracture in elderly patients[J].zhongguo gu shang / China J Orthop Trauma ,2019,32(5):444~447
阅读全文  下载  查看/发表评论  下载PDF阅读器
关闭




版权所有:《中国骨伤》杂志社京ICP备12048066号-2  版权声明
地址:北京市东直门内南小街甲16号,100700
电话:010-64089487 传真:010-64089792 Email:zggszz@sina.com

京公网安备 11010102004237号